[SMLE] Undiagnosed Lambert-Eaton Myasthenic Syndrome in the Era of Sugammadex: A Case Report

[RSS-Bot]

Clin Neuropharmacol. 2023 Nov-Dec 01;46(6):205-208. doi: 10.1097/WNF.0000000000000569. Epub 2023 Sep 11.

ABSTRACT

OBJECTIVE: In this case report, we discuss the rare manifestation of prolonged neuromuscular blockade in a patient with history of small cell lung cancer and undiagnosed Lambert-Eaton myasthenic syndrome (LEMS) who had previously received succinylcholine for general anesthesia without incident but subsequently exhibited prolonged neuromuscular blockade during a laparoscopic procedure. We aimed to emphasize the importance of reversal agent safety and precision as well as vigilant perioperative and postoperative care.

METHODS: We used the patient's electronic medical record, direct patient care experiences, and comprehensive literature review for this case report.

RESULTS: Sugammadex was administered with mild improvement. Suspecting undiagnosed LEMS, neostigmine was administered, yielding satisfactory muscle strength and successful extubation. In retrospect, the patient reported history of weakness when lifting weights that improved upon exertion.

CONCLUSIONS: Sugammadex is an efficient and effective agent for reversal of neuromuscular blockade. However, proper monitoring of the depth and recovery of blockade is imperative to when using sugammadex with optimal safety and precision in all patients. Perioperative care teams must remain vigilant with a high index of suspicion for neuromuscular junction pathology to properly plan perioperative care for patients at risk, especially those with small cell lung cancer who may have undiagnosed LEMS.

PMID:37962306 | DOI:10.1097/WNF.0000000000000569


Source: https://pubmed.ncbi.nlm.nih.gov/3796230 ... t6+86293ac